00:45 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

Onapristone: Ph II halted

Arno said it halted enrollment in the Phase II portion of an open-label, U.K. Phase I/II trial evaluating twice-daily onapristone plus Zytiga abiraterone acetate after the company determined further enrollment was not justified based on...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

AR-42 regulatory update

The European Commission granted Orphan Drug designation for Arno's AR-42 to treat meningioma and schwannoma. The compound is in Phase I/IIa testing to treat multiple myeloma (MM), chronic lymphocytic leukemia (CLL), lymphoma and solid tumors....
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

AR-42 regulatory update

Arno said the European Commission granted Orphan Drug designation for AR-42 to treat neurofibromatosis type 2. The compound is in Phase I/IIa testing to treat multiple myeloma (MM), chronic lymphocytic leukemia (CLL), lymphoma and solid...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

AR-42 regulatory update

FDA granted Orphan Drug designation for Arno's AR-42 to treat CNS tumors. The broad-spectrum deactylation inhibitor of histone and non-histone proteins that regulate gene expression is in Phase I/IIa testing to treat multiple myeloma (MM),...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Clinical News

AR-42: Phase I/IIa started

Arno began an open-label, dose-escalation, U.S. Phase I/IIa trial to evaluate oral AR-42 in about 50 patients. Arno Therapeutics Inc. (Pink:ARNI), Pasippany, N.J.   Product: AR-42   Business: Cancer   Molecular target: NA   Description: Oral compound that...
07:00 , Jun 9, 2008 |  BC Week In Review  |  Company News

Arno, Laurier International Inc. deal

Arno acquired public shell company Laurier for $22.6 million in a reverse merger. Arno also raised $18 million in a private placement. Arno will retain its headquarters and management and will trade under the symbol...
07:00 , Jun 9, 2008 |  BioCentury  |  Finance

Ebb & Flow

Having gotten his hands on 215 pages of documents fromBiogen Idec (NASDAQ:BIIB) under judicial order by the Delaware Chancery Court, activist investor Carl Icahn last week leveled new charges that at least one potential acquirer...